NanoViricides(NNVC)

Focus: NanoViricides develops nanotechnology-based biomimetic antiviral medicines, leveraging proprietary nanoparticle platforms to create novel viral therapeutics. The company is a publicly traded, pre-revenue stage biotech with minimal commercial traction.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About NanoViricides

AI assessmentNot Hiring

No open roles listed right now. Follow NanoViricides to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

FY2025

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2005

SEC Filings: 2 available

Help build intelligence for NanoViricides

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exclusive access to proprietary nanotechnology platform with 18+ years of IP development since 2005 founding
Opportunity to shape early-stage antiviral pipeline in an emerging nanotech space with minimal competitive noise
Public company status provides equity upside potential with defined governance and reporting transparency

Watch Out For

Zero clinical programs in active development (no Phase 1/2/3 trials reported) creates immediate pathway uncertainty and career momentum risk
Severe cash burn with $8.3M net loss in FY2025 against $5M cash on hand—runway of 6-12 months without funding raises existential risk

Generated by Claude from NanoViricides's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Financials (FY2025)

Revenue

R&D Spend

$5M15%

Net Income

-$8M

Cash

$5M

Source: SEC 10-K Filing

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo